Claritas Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Claritas Pharmaceuticals has a total shareholder equity of $3.3M and total debt of $538.0K, which brings its debt-to-equity ratio to 16.4%. Its total assets and total liabilities are $11.0M and $7.7M respectively. Claritas Pharmaceuticals's EBIT is $485.0K making its interest coverage ratio 0.2. It has cash and short-term investments of $2.0K.
Key information
16.4%
Debt to equity ratio
US$538.00k
Debt
Interest coverage ratio | 0.2x |
Cash | US$2.00k |
Equity | US$3.28m |
Total liabilities | US$7.74m |
Total assets | US$11.02m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CLAS's short term assets ($11.0M) exceed its short term liabilities ($7.7M).
Long Term Liabilities: CLAS's short term assets ($11.0M) exceed its long term liabilities ($10.0K).
Debt to Equity History and Analysis
Debt Level: CLAS's net debt to equity ratio (16.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CLAS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CLAS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: CLAS's interest payments on its debt are not well covered by EBIT (0.2x coverage).